| CAS NO: | 122841-12-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 620.64 |
|---|---|
| Formula | C19H22N8O6S2.H2SO4 |
| CAS No. | 122841-12-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 3 mg/mL (4.8 mM) |
| Water: 5 mg/mL (8.0 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid compound with sulfuric acid (1:1) InChi Key: LZOLCSVRFKCSEM-ZQCAECPKSA-N InChi Code: InChI=1S/C19H22N8O6S2.H2O4S/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28;1-5(2,3)4/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32);(H2,1,2,3,4)/b20-11?,24-12-;/t13-,17-;/m1./s1 SMILES Code: O=C(C(N12)=C(CN3N(CCO)C(C=C3)=N)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O.O=S(O)(O)=O |
| Synonyms | FK 037 Sulfate; FK037; FK-037 |
| In Vitro | In vitro activity: Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. |
|---|---|
| In Vivo | Cefoselis elicits a massive elevation of extracellular glutamate concentration in normal rats. Cefoselis (50 mg/animal)-induced convulsions are prevented by pretreatment with 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), diazepam and phenobarbital (ED(50) values (mg/kg) of 0.78, 1.59 and 33.0, respectively), but not by carbamazepine or phenytoin. |
| Animal model | Rats |
| Formulation & Dosage | 50 mg/animal |
| References | Br J Pharmacol. 2002 Jan;135(2):427-32; J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. |
m.cnreagent.com